Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $345 from $360 and keeps an Equal Weight rating on the shares. The firm says 2025 will be about self-help and new management executing on margins and free cash flow. Valuation has moved up, but still implies status quo, it adds. Wells sees Bio-Rad as more a second half of the year story when visibility on 2026/2027 EPS/free cash flow power improves.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue